PL3318259T3 - Stabilna kompozycja farmaceutyczna do podawania doustnego - Google Patents

Stabilna kompozycja farmaceutyczna do podawania doustnego

Info

Publication number
PL3318259T3
PL3318259T3 PL16821324.7T PL16821324T PL3318259T3 PL 3318259 T3 PL3318259 T3 PL 3318259T3 PL 16821324 T PL16821324 T PL 16821324T PL 3318259 T3 PL3318259 T3 PL 3318259T3
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
oral administration
stable pharmaceutical
stable
oral
Prior art date
Application number
PL16821324.7T
Other languages
English (en)
Inventor
Masakazu Miyazaki
Ryohei ISHIBA
Yuki Takaishi
Fumiaki Uejo
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57686183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3318259(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of PL3318259T3 publication Critical patent/PL3318259T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL16821324.7T 2015-07-03 2016-07-01 Stabilna kompozycja farmaceutyczna do podawania doustnego PL3318259T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015134817 2015-07-03
PCT/JP2016/069615 WO2017006855A1 (ja) 2015-07-03 2016-07-01 安定な経口投与用医薬組成物

Publications (1)

Publication Number Publication Date
PL3318259T3 true PL3318259T3 (pl) 2023-05-02

Family

ID=57686183

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16821324.7T PL3318259T3 (pl) 2015-07-03 2016-07-01 Stabilna kompozycja farmaceutyczna do podawania doustnego

Country Status (21)

Country Link
US (9) US10786500B2 (pl)
EP (2) EP3318259B1 (pl)
JP (2) JP6132294B1 (pl)
KR (1) KR102685890B1 (pl)
CN (1) CN107847500B (pl)
CA (1) CA2989534C (pl)
DK (1) DK3318259T3 (pl)
ES (1) ES2940306T3 (pl)
FI (1) FI3318259T3 (pl)
HR (1) HRP20230253T1 (pl)
HU (1) HUE061697T2 (pl)
LT (1) LT3318259T (pl)
MX (1) MX378947B (pl)
PH (1) PH12017502252B1 (pl)
PL (1) PL3318259T3 (pl)
PT (1) PT3318259T (pl)
RS (1) RS64070B1 (pl)
SI (1) SI3318259T1 (pl)
SM (1) SMT202300074T1 (pl)
TW (1) TWI756177B (pl)
WO (1) WO2017006855A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11045468B2 (en) * 2014-02-04 2021-06-29 Astellas Pharma Inc. Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
EP3318259B1 (en) 2015-07-03 2023-01-11 Astellas Pharma Inc. Stable pharmaceutical composition for oral administration
MY204603A (en) 2019-04-03 2024-09-05 Astellas Pharma Inc Pharmaceutical composition
WO2022009235A1 (en) * 2020-07-10 2022-01-13 Msn Laboratories Private Limited, R&D Center Process for the preparation of gilteritinib fumarate
MX2024008057A (es) 2021-12-30 2024-08-28 Biomea Fusion Inc Compuestos de pirazina como inhibidores de flt3.
WO2025240494A1 (en) 2024-05-13 2025-11-20 Lumen Bioscience, Inc. Leptin compositions and methods of making and using the same to support weight loss and/or maintenance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9314454B2 (en) * 2007-12-28 2016-04-19 Sawai Pharmaceutical Co., Ltd. Oral cavity disintegrating tablet and method of producing the same
LT3009428T (lt) * 2009-05-08 2018-04-10 Astellas Pharma Inc. Diamino heterociklinis karboksamido junginys
JP6111202B2 (ja) 2011-01-07 2017-04-05 ノバルティス アーゲー 免疫抑制製剤
US11045468B2 (en) 2014-02-04 2021-06-29 Astellas Pharma Inc. Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
TW201613579A (en) 2014-06-24 2016-04-16 Astellas Pharma Inc Pharmaceutical composition for oral administration
EP3318259B1 (en) * 2015-07-03 2023-01-11 Astellas Pharma Inc. Stable pharmaceutical composition for oral administration
US9755832B2 (en) 2015-12-29 2017-09-05 International Business Machines Corporation Password-authenticated public key encryption and decryption

Also Published As

Publication number Publication date
JP6132294B1 (ja) 2017-05-24
US11938133B2 (en) 2024-03-26
JP6798400B2 (ja) 2020-12-09
HK1248544A1 (zh) 2018-10-19
US20230129146A1 (en) 2023-04-27
RS64070B1 (sr) 2023-04-28
RU2018103354A (ru) 2019-08-05
JPWO2017006855A1 (ja) 2017-07-13
TW201716069A (zh) 2017-05-16
CA2989534C (en) 2023-08-01
CA2989534A1 (en) 2017-01-12
US20230301992A1 (en) 2023-09-28
DK3318259T3 (en) 2023-03-06
KR102685890B1 (ko) 2024-07-19
CN107847500B (zh) 2021-08-10
EP4230208A1 (en) 2023-08-23
LT3318259T (lt) 2023-05-10
WO2017006855A1 (ja) 2017-01-12
US20180185359A1 (en) 2018-07-05
EP3318259A1 (en) 2018-05-09
US20230310422A1 (en) 2023-10-05
TWI756177B (zh) 2022-03-01
US11938131B2 (en) 2024-03-26
US10786500B2 (en) 2020-09-29
RU2018103354A3 (pl) 2019-11-28
MX2017016862A (es) 2018-04-24
EP3318259B1 (en) 2023-01-11
RU2764750C2 (ru) 2022-01-20
US20200383977A1 (en) 2020-12-10
FI3318259T3 (fi) 2023-03-20
EP3318259A4 (en) 2019-02-27
PH12017502252A1 (en) 2018-05-28
ES2940306T3 (es) 2023-05-05
SMT202300074T1 (it) 2023-05-12
CN107847500A (zh) 2018-03-27
US20230277531A1 (en) 2023-09-07
JP2017119728A (ja) 2017-07-06
US20230277532A1 (en) 2023-09-07
US11944620B2 (en) 2024-04-02
MX378947B (es) 2025-03-11
KR20180023914A (ko) 2018-03-07
PH12017502252B1 (en) 2023-10-11
US20230277530A1 (en) 2023-09-07
SI3318259T1 (sl) 2023-06-30
HRP20230253T1 (hr) 2023-04-28
US11938130B2 (en) 2024-03-26
PT3318259T (pt) 2023-03-20
HUE061697T2 (hu) 2023-08-28
US20230277529A1 (en) 2023-09-07
US11938132B2 (en) 2024-03-26

Similar Documents

Publication Publication Date Title
IL268316B (en) Pharmaceutical preparations for combined treatment
IL253719A0 (en) Pharmaceutical preparations for combination therapy
IL270812A (en) Solid compositions for oral drug administration
PL4233846T3 (pl) Formulacje farmaceutyczne
IL256491A (en) Pharmaceutical formulations
ZA201605263B (en) Pharmaceutical composition for topical administration
ZA201703562B (en) Pharmaceutical composition for oral administration comprising taxane
ZA201601656B (en) Inhalable pharmaceutical composition
PL3318259T3 (pl) Stabilna kompozycja farmaceutyczna do podawania doustnego
ZA201707094B (en) Pharmaceutical formulations
EP3290037A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
IL262204A (en) Granular formulation for oral administration
SI3157506T1 (sl) Oralni farmacevtski sestavek z zamaskiranim okusom
PT3650024T (pt) Composição farmacêutica para administração nasal compreendendo rifampicinas para tratar demência
EP3162368A4 (en) Pharmaceutical composition for oral administration
EP2979698A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
PT3377044T (pt) Composições de ibuprofeno para administração oral direta
EP3326652A4 (en) Pharmaceutical composition for oral administration comprising high concentration taxane